

Drug Repurposing: A Sustainable Approach to Medicinal Chemistry

Nikal Khalim*

Department of Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany

Introduction

The search for new drugs has traditionally been a lengthy and resource-intensive process, often involving the synthesis and testing of thousands of compounds. However, drug repurposing, also known as drug repositioning, offers a more sustainable approach to medicinal chemistry. This article explores the concept of drug repurposing, its advantages, challenges, and its potential to revolutionize the pharmaceutical industry. We will also discuss key examples of successful drug repurposing and the future prospects of this innovative approach.

The discovery and development of new drugs have been critical in improving healthcare and extending human life expectancy. Historically, the drug discovery process has been a laborious and costly endeavor, often taking more than a decade to bring a new drug to market and costing billions of dollars. However, in recent years, the concept of drug repurposing has gained prominence as a sustainable approach to medicinal chemistry. Drug repurposing, also known as drug repositioning, involves identifying new therapeutic uses for existing drugs that were initially developed for different indications. This approach offers several advantages over traditional drug discovery methods, including reduced development timelines, lower costs, and a higher probability of success. In this article, we will delve into the world of drug repurposing, exploring its advantages, challenges, and its potential to revolutionize the pharmaceutical industry [1].

Description

One of the most significant advantages of drug repurposing is the reduced development time. Unlike *de novo* drug discovery, where new compounds must be synthesized and extensively tested, repurposing leverages existing drugs with established safety profiles. This significantly shortens the time it takes to bring a drug to market. For example, if a drug has already undergone clinical trials for safety and efficacy, the regulatory process for a new indication may be expedited. Safety is a paramount concern in drug development. Repurposed drugs, with their established safety profiles, offer a level of confidence that is often lacking in entirely new compounds. This can lead to a more straightforward regulatory approval process and a reduced risk of unforeseen adverse effects in patients [2].

The pharmaceutical industry faces notoriously high attrition rates, with many drug candidates failing to make it through clinical trials. Drug

repurposing can help mitigate this risk since repurposed drugs have already demonstrated safety and efficacy to some extent. Consequently, the success rate for repurposed drugs tends to be higher than that of entirely new compounds. One of the primary challenges in drug repurposing is identifying new therapeutic indications for existing drugs. This requires a deep understanding of the drug's mechanism of action and its potential relevance to other diseases. Computational approaches, data mining, and high-throughput screening have become valuable tools in this regard, helping researchers identify potential candidates for repurposing.

Navigating intellectual property issues can be complex when repurposing a drug. The original patent holder may still hold rights to the drug for its original indication, making it challenging for other companies or researchers to develop the drug for a new use. Legal and licensing agreements must be carefully negotiated to avoid infringement. Competition can be fierce when repurposing a drug for a new indication. Multiple companies or researchers may have the same idea, leading to a race to bring the repurposed drug to market. This can create challenges in terms of securing funding, conducting clinical trials, and gaining regulatory approval [3].

Originally developed as a treatment for angina and hypertension, Viagra (sildenafil) gained fame for its unexpected side effect: the treatment of erectile dysfunction. This repurposing of the drug led to a blockbuster pharmaceutical product. Thalidomide, once infamous for causing birth defects, found a new lease on life as a treatment for multiple myeloma. Its immunomodulatory properties made it an effective therapy for this rare and challenging cancer. Aspirin, a common over-the-counter pain reliever, was originally developed by Bayer in the late 19th century. It has since been repurposed for a variety of uses, including the prevention of heart attacks and strokes [4].

The future of drug repurposing looks promising. Advances in computational biology and artificial intelligence are making it easier to identify potential candidates for repurposing. Additionally, collaborations between pharmaceutical companies, academic institutions, and government agencies are fostering innovation in this field. Furthermore, the growing emphasis on personalized medicine and the identification of biomarkers associated with disease are opening new avenues for drug repurposing. By understanding the underlying genetic and molecular factors of diseases, researchers can identify existing drugs that may be effective in treating specific patient populations.

The possibility of modifying the properties of organic ligands and their derivatives by varying the metallic chelate and the ligands opens the door for the addition of other roles as well as antioxidant performance. While linking antioxidant active groups improves antioxidant performance, it is still ineffective for discovering antioxidant performance for previously produced antioxidant active group chelates, as well as preparing novel antioxidant active group chelates with extra properties. Metal complexes' molecular structure diversity has been identified as promising for the discovery and application of new antioxidant compounds. This review covered the improvement in antioxidant activity achieved with coordination to a wide range of metal centres and demonstrated that various factors are involved in a metal complex's antioxidant activity [5].

*Address for Correspondence: Nikal Khalim, Department of Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany, E-mail: nikalkhalim@gmail.com

Copyright: © 2023 Khalim N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 02 August, 2023, Manuscript No. mccr-23-112827; Editor Assigned: 04 August, 2023, PreQC No. P-112827; Reviewed: 16 August, 2023, QC No. Q-112827; Revised: 21 August, 2023, Manuscript No. R-112827; Published: 28 August, 2023, DOI: 10.37421/2161-0444.2023.13.681

Conclusion

Drug repurposing offers a sustainable and cost-effective approach to medicinal chemistry. With its potential to reduce development timelines, lower costs, and improve success rates, it has become an attractive strategy for both the pharmaceutical industry and academic researchers. While challenges such as identifying new indications and navigating intellectual property issues exist, the rewards of repurposing existing drugs for new uses are substantial. As technology and our understanding of disease continue to advance, drug repurposing is poised to play an increasingly significant role in improving global healthcare and expanding the pharmaceutical industry's reach.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel and Mathieu Laversanne, et al. "Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries." *CA Cancer J Clin* 71 (2021): 209-249.
2. Whiteman, David C., Adele C. Green and Catherine M. Olsen. "The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031." *J Invest Dermatol* 136 (2016): 1161-1171.
3. Nabirotkin, Serguei, Alex E. Peluffo, Philippe Rinaudo and Jinchao Yu, et al. "Next-generation drug repurposing using human genetics and network biology." *Curr Opin Pharmacol* 51 (2020): 78-92.
4. Ávalos-Moreno, Marta, Araceli López-Tejada, Jose L. Blaya-Cánovas and Francisca E. et al. "Drug repurposing for triple-negative breast cancer." *J Pers Med* 10 (2020): 200.
5. Xu, Zhiwei, Xiaojian Liu, and Daoping Zhuang. "Artesunate inhibits proliferation, migration, and invasion of thyroid cancer cells by regulating the PI3K/AKT/FKHR pathway." *Biochem Cell Biol* 100 (2022): 85-92.

How to cite this article: Khalim, Nikal. "Drug Repurposing: A Sustainable Approach to Medicinal Chemistry." *J Med Chem* 13 (2023): 681.